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Abstract
Background: In proliferative diabetic retinopathy (PDR), vascular endothelial growth factor (VEGF) and connective tissue
growth factor (CTGF) cause blindness by neovascularization and subsequent fibrosis, but their relative contribution to both
processes is unknown. We hypothesize that the balance between levels of pro-angiogenic VEGF and pro-fibrotic CTGF
regulates angiogenesis, the angio-fibrotic switch, and the resulting fibrosis and scarring.
Methods/Principal Findings: VEGF and CTGF were measured by ELISA in 68 vitreous samples of patients with proliferative
DR (PDR, N=32), macular hole (N=13) or macular pucker (N=23) and were related to clinical data, including degree of
intra-ocular neovascularization and fibrosis. In addition, clinical cases of PDR (n=4) were studied before and after pan-retinal
photocoagulation and intra-vitreal injections with bevacizumab, an antibody against VEGF. Neovascularization and fibrosis
in various degrees occurred almost exclusively in PDR patients. In PDR patients, vitreous CTGF levels were significantly
associated with degree of fibrosis and with VEGF levels, but not with neovascularization, whereas VEGF levels were
associated only with neovascularization. The ratio of CTGF and VEGF was the strongest predictor of degree of fibrosis. As
predicted by these findings, patients with PDR demonstrated a temporary increase in intra-ocular fibrosis after anti-VEGF
treatment or laser treatment.
Conclusions/Significance: CTGF is primarily a pro-fibrotic factor in the eye, and a shift in the balance between CTGF and
VEGF is associated with the switch from angiogenesis to fibrosis in proliferative retinopathy.
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Introduction
Blindness from proliferative diabetic retinopathy (PDR) is
caused by angiogenesis and fibrosis in the vitreous cavity of the
eye [1–4]. PDR is a wound healing-like response in which
neovascularization is accompanied by influx of inflammatory cells
and development of myofibroblasts. This progresses to a fibrotic
phase with fibrovascular contraction causing haemorrhages,
retinal detachment and inevitable blindness. Several growth
factors have been shown to play a role in PDR, e.g. vascular
endothelial growth factor-A (VEGF), transforming growth factor-
ß, hepatocyte growth factor, platelet-derived growth factor, and
the pro-fibrotic connective tissue growth factor (CTGF) [5,6].
VEGF is considered to be the primary angiogenesis factor in this
sequence of events [7–9]. In contrast, the causal factors of fibrosis
and scarring and the regulation of the transition from angiogenesis
to the fibrotic phase of PDR, which we propose to call the angio-
fibrotic switch, remain largely unknown. We have recently shown
that vitreous levels of CTGF correlate strongly with degree of
fibrosis in vitreo-retinal disorders [10]. In other organs than the
eye, CTGF has a similar role and has been identified as a potential
therapeutic target for inhibition of pathological fibrosis [11–15].
Interestingly, CTGF is upregulated by VEGF [16–18] and
inhibits VEGF-induced angiogenesis by formation of VEGF-
CTGF complexes [19,20], suggesting a negative feedback function
of CTGF on VEGF-induced angiogenesis. In contrast, recombi-
nant CTGF has been shown to cause angiogenesis in the cornea
and in other in vivo models in addition to its pro-fibrotic properties
[21,22]. Other findings, such as co-localization of CTGF and
VEGF in human subretinal neovascularization [23], and increased
CTGF levels in vitreous of PDR patients with active neovascu-
larization [24], also suggested that CTGF has a causal role in
ocular neovascularization. However, we have recently challenged
this concept by showing that in CTGF knock-out mice,
angiogenesis is not impaired in several experimental models of
neovascularization [25].
Based on these findings we propose a novel concept. We
hypothesize that CTGF is a primary causal factor in sight-
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2675threatening fibrosis in the eye, and that an equilibrium shift in the
balance between VEGF and CTGF levels in vitreous regulates the
switch from the angiogenic phase to fibrosis in conditions such as
PDR. Therefore, we investigated vitreous VEGF and CTGF levels
in correlation with degree of fibrosis and neovascularization in a
series of patients with PDR and other vitreoretinal disorders, and




We investigated 68 vitreous samples of patients with PDR
(N=32), macular hole (N=13) and idiopathic macular pucker
(N=23), who were operated by pars plana vitrectomy. The study
was conducted according to the Declaration of Helsinki and
approved by the institutional review board of the Academic
Medical Center at the University of Amsterdam. Informed written
consent was obtained from each patient.
Clinical data, which allowed grading of fibrosis, activity of
neovascularization, degree of haemorrhage, and presence and type
of diabetes, were obtained from the pre-operative ophthalmic and
ultrasound examinations, the patient files and from per-operative
observations, using a standardized form. Fibrosis was graded as 0
when there was no fibrosis, as 1 when there were a few pre-retinal
membranes (as limited as in macular pucker), as 2 when white pre-
retinal fibrotic membranes with limited extension into the vitreous
were present, and as 3 when abundant white membranes reaching
into the vitreous body were observed. Neovascularization was
graded as 0 when absent, as 1 (quiescent) when only non-perfused
vessels were present, and as 2 (active) when there were perfused
preretinal capillaries [26]. Degree of haemorrhage was graded as 0
when all media were clear and all fundus details were visible, as 1
when media were a little clouded but the fundus could still be
examined, as 2 when the disk was obscured by haemorrhage, and
as 3 when fundus details could not be obtained.
Inaddition, we investigatedretrospectively,after informedconsent,
the clinical records of 4 patients with PDR and one patient with
proliferative retinopathy as a complication of branch retinal vein
occlusion, who were treated with either pan-retinal photocoagulation
(2 cases of PDR and the case of branch retinal vein occlusion) or with
intravitreal injections with bevacizumab, an anti-VEGF agent,
followed by pan-retinal laser treatment (2 cases of PDR).
Sample collection
Undiluted vitreous samples (0.5–1 ml) were obtained by using a
vitrectome at the start of a classic three-port pars plana vitrectomy
with the infusion line in position but not opened. The vitreous was
transferred to sterile Eppendorf tubes and immediately frozen in
dry ice. The samples were kept at 280uC until assayed.
Measurement of CTGF and VEGF levels by enzyme-linked
immunosorbent assays (ELISA)
After thawing, vitreous samples were centrifuged at 14.000 rpm
for 15 minutes at 4uC, and supernatant was collected. Concen-
trations of CTGF were measured in samples by means of sandwich
ELISAs, using two distinct monoclonal antibodies specifically
recognizing the N-terminal part of the CTGF protein (FibroGen,
San Francisco CA, USA) as described previously [10]. Purified
recombinant human CTGF (FibroGen) was used as standard.
Concentrations of VEGF165 were determined by means of
sandwich ELISA according to the manufacturer’s protocol
(R&D Systems, Minneapolis MS, USA). All ELISAs were carried
out in duplicate.
Statistical analysis
Both CTGF and VEGF levels were tested for normal
distribution using the Shapiro-Wilk test (W.0.90). VEGF levels
in vitreous showed a right skewed distribution and were log10
transformed to obtain a normal distribution. Associations between
gender, age, diabetes type, degree of neovascularization, degree of
haemorrhage and degree of fibrosis were assessed by ANOVA
with correction for age and gender (included as covariates) where
appropriate, and for unequal variances due to inter-assay
variability. Least square means were estimated based on the
model and, in case of an overall significant difference, compared
using a post-hoc test. The correlation between CTGF and
log10(VEGF) is expressed as Spearman correlation coefficient. In
addition, univariate and multiple ordinal logistic regression
analyses were performed with degree of fibrosis or neovascular-
ization activity as dependent (outcome) variables. These effects
were expressed as odds ratios with a 95% confidence interval. A
two-tailed p-value ,0.05 was considered statistically significant.
All analyses were carried out using SAS (Version 9) software (SAS
Institute, Cary NC, USA).
Results
Analysis of all patients
The research variables and characteristics of the 68 patients
studied are shown in Table 1. There was a significant difference in
age between the patients diagnosed with a macular hole or
macular pucker and patients with PDR (66.4 versus 54.2,
respectively; p=0.001). Mean vitreous levels of CTGF and
log10(VEGF) were significantly higher in patients with PDR than
in patients diagnosed with a macular hole or macular pucker
(p,0.001 for both growth factors, corrected for age (covariate)).
Univariate analysis of all 68 patients showed that CTGF and
log10(VEGF) levels in vitreous correlated strongly (p,0.001). A
scatter plot of the correlation between CTGF levels and
log10(VEGF) levels is shown (Figure 1). Univariate analysis of all
68 patients also showed that levels of both growth factors were
associated with diabetes-associated variables (i.e. the presence of
diabetes, degree of neovascularization, fibrosis and haemorrhage;
all p,0.001). CTGF and log10(VEGF) levels did not differ between
genders. Log10(VEGF) levels were not associated with age, whereas
CTGF levels were (p=0.03). Multivariate analysis showed that
mean CTGF levels were only associated with degree of fibrosis
(p,0.001), whereas log10(VEGF) levels were only significantly
associated with degree of neovascularization (p,0.001).
Analysis of patients with PDR
Most parameters which correlated with VEGF and CTGF
levels were associated with diabetes (i.e. neovascularization,
haemorrhage and fibrosis) in the group of 68 patients. However,
the 13 macular hole patients and 23 macular pucker patients did
not suffer from diabetes (Table 1). Therefore, to exclude this
confounder, we repeated the statistical analysis on the data of the
32 patients with PDR who all had diabetes. Similar to the entire
patient population, CTGF levels in the vitreous of patients with
PDR were significantly associated with degree of fibrosis
(p=0.042), and not significantly with degree of neovascularization
(p=0.072), whereas log10(VEGF) levels were associated with
degree of neovascularization (p=0.011), and not with degree of
fibrosis (p=0.665) (Figure 1). We also evaluated the association
between the ratio CTGF/log10(VEGF) and degree of fibrosis or
degree of neovascularization, respectively. The ratio CTGF/
log10(VEGF) was associated with degree of fibrosis (p=0.009), but
not with degree of neovascularization (p=0.635) (Figure 2).
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VEGF) levels was 0.4 (p=0.01). Age, gender, degree of
haemorrhage did not show an association with CTGF or
log10(VEGF) levels (p.0.05).
In a separate analysis, an ordinal logistic regression model with
degree of fibrosis as dependent (outcome) variable was used to sort
out the strongest predictive variable for fibrosis. Univariate ordinal
logistic regression model analysis (Table 2) showed that vitreous
levels of CTGF and CTGF/log10(VEGF) ratios were associated
with fibrosis. The association was not found between log10(VEGF)
levels and degree of fibrosis but it was found between log10(VEGF)
levels and degree of neovascularization.
In a multifactorial model with both CTGF and log10(VEGF)
levels as predictors for degree of fibrosis, both CTGF (p=0.008)
and log10(VEGF) (p=0.033) were associated with degree of
fibrosis: CTGF associated positively with an odds ratio of 1.19 (95%
CI: 1.05–1.36) whereas log10(VEGF) levels showed a negative
association with an odds ratio of 0.06 (95% CI: 0.01–0.80). These
findings explain the strong association between CTGF/log10(-
VEGF) ratios and fibrosis in the univariate analysis.
Clinical course of proliferative retinopathy after laser or
anti-VEGF treatment
In each of the 4 cases of PDR, we observed a transition from
pre-retinal angiogenesis to a temporary phase of progressing pre-
retinal fibrosis after pan-retinal laser treatment, or after anti-
VEGF treatment followed by pan-retinal laser (Figure 3). In the
case of branch retinal vein occlusion complicated by local pre-
retinal angiogenesis with leaky vessels due to ischemia, the new
Table 1. Characteristics of the 68 patients included in the study.
Patient characteristics (n=68) Subcategory Macular hole (n=13) PDR (n=32)
Macular pucker (n=23)
Age (mean6SD) 66?4614?65 4 ?2612?7
Gender Male 15 15
Female 21 17
Patients with diabetes Total 0 32
Type I 16
Type II 16
Degree of neovascularization No neovascularization (0) 36 2
Quiescent neovascularization (1) 11
Active neovascularization (2) 19
Degree of haemorrhage No haemorrhage (0) 36 11
Media little clouded (1) 4
Disc obscured (2) 11
No fundus detail visible (3) 6
Degree of fibrosis No fibrosis (0) 13 0
Only a few pre-retinal membranes (1) 23 2
Some proliferative membranes (2) 17
Abundant proliferative membranes (3) 13
CTGF (geom. mean, 95% CI) 13?0 ng/ml [10.8–15.3] 24.1 ng/ml [20.5–27.7]
VEGF (geom. mean, 95% CI) 123 pg/ml [95–159] 776 pg/ml [566–1065]
Ratio CTGF/log10(VEGF) 3.42 [2.7–4.2] 6.2 [5.3–7.1]
Abbreviations: PDR, proliferative diabetic retinopathy; SD, standard deviation; VEGF, vascular endothelial growth factor; CTGF, connective tissue growth factor.
doi:10.1371/journal.pone.0002675.t001
Figure 1. Correlation between the levels of CTGF and
log10(VEGF) in the vitreous of all 68 patients. A significant
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treatment, whereas fibrosis did not follow (Figure 4).
Discussion
The observations presented in this study, set against the
background of existing literature on VEGF and CTGF, prompt
us to propose a novel concept of the regulation of angiogenesis and
fibrosis in ocular disease, and in wound healing in general. In this
concept, angiogenesis in the vitreous is driven by VEGF, which
amongst other factors upregulates the pro-fibrotic factor CTGF in
various cell types in the newly formed neovascular membranes.
Increasing levels of CTGF inactivate VEGF by reduction of
production and complex formation, and when the equilibrium
between these two factors shifts to a certain threshold ratio, the
angio-fibrotic switch occurs and fibrosis driven by excess CTGF
leads to scarring and blindness. This concept identifies CTGF as a
major potential therapeutic target in the treatment of ocular
fibrosis, in particular in combination with anti-VEGF agents.
What is the evidence that this concept may be true? We have
previously shown that vitreous CTGF levels strongly correlate with
degree of fibrosis in vitreo-retinal conditions [10], an observation
which is in line with the established role of CTGF in pathological
fibrosis in otherorgans [11–13,27–31]. However, exogenous CTGF
has been reported to have angiogenic effects in ocular experimental
models [21,22,24,32]. The present study shows that, in human
PDR, the CTGF levels and the ratio of CTGF over VEGF are
strongly associated with the presence and degree of fibrosis, whereas
CTGFlevels,in contrast to VEGF levels,do not have an association
with neovascularization. Moreover, multivariate analysis revealed
that degree of fibrosis was best predicted by the ratio of CTGF over
VEGF. VEGF levels do correlate significantly with active
neovascularization, in agreement with the widely accepted role of
VEGF as a major ocular angiogenic factor [7,8,26,33–35]. We have
previously shown that CTGF expression is induced by AGEs in
diabetic rat retinas [36], particularly in pericytes [37]. We also have
shown in various animal models using CTGF
+/2 heterozygous and
CTGF
2/2 homozygous CTGF-deficient mice that diminished
levels or even complete absence of CTGF did not affect
neovascularization significantly [25]. These findings support our
concept as outlined above.Our findings question the applicability of
the concept of CTGF-driven angiogenesis to in vivo ocular disease.
Rather, the accumulated evidence indicates that CTGF effects are
highly context dependent and, in the specific condition of PDR,
cause fibrosis rather than angiogenesis. Observations by others in
PDR patients after VEGF inhibition by intravitreal injections with
bevacizumab [38–40] may sustain this assumption. In these
patients, a remarkable inhibition of angiogenesis is observed. We
like to suggest that elevated CTGF levels, which remain in the
vitreous after VEGF inhibition, are not able to maintain the
angiogenic response, providing further evidence that CTGF has no
pro-angiogenic role in PDR.
PDR and other proliferative retinopathies, which represent
important causes of blindness, are caused by widespread retinal
ischemia.Intheseconditions,pre-retinalneovascularizationintothe
vitreous is the first sign that a fibrovascular wound healing reaction
will develop in later stages. VEGF produced by the ischemic retina
is considered to be the major causal growth factor in the
neovascularization process [8]. In later stages of PDR, scarring
mechanisms within the fibrovascular membranes become more
important, and fibrosis and vitreoretinal traction cause retinal
detachment and blindness [1,3,4,9]. The mechanisms causing this
transition, the angio-fibrotic switch, have not been elucidated.
Further analysis of human vitreous samples in our study
demonstrated a significant correlation between CTGF and log10
(VEGF) levels. Thismayrelate to the factthatVEGFandCTGFare
both direct targets of factors such as glucose and AGEs, inherent to
the diabetic condition. It may also reflect that VEGF induces CTGF
expressioninthe eye,ashasbeendemonstrated inretinalendothelial
cells in vitro [16,17] and in the rat retina in vivo [18,36]. The
consequent rise of the ratio of CTGF over VEGF may contribute to
the angio-fibrotic shift occurring during progression of PDR: it has
been reported that CTGF can influence VEGF availability on
different levels, including direct protein-protein binding [19,20,41]
and degradation ofHIF-1a,whichisa transcription factor for VEGF
[42]. Angiogenesis may thus decline due to inactivation of VEGF by
CTGF. Subsequent fibrosis may be induced by excess of unbound
CTGFas wasfound inkidney [15,43] andskin[30]. An earlier study
by Kita et al. [44] did not show a significant correlation between
CTGF and VEGF in the vitreous of patients with PDR and
proliferative vitreoretinopathy. The reason for the difference with
the current results is unknown, but may lie in the fact that we
analyzed vitreous of PDR patients only.
Our observations that vitreous VEGF levels were significantly
higher in active neovascularization than in quiescent neovascu-
larization, and were negatively associated to degree of fibrosis,
support this concept. It may, however, not be ruled out that other
factors such as fibronectin, integrins and proteoglycans have an
Figure 2. Mean levels of CTFG (A, D), geometric mean levels of
VEGF (B, E), and mean ratio CTGF/log10(VEGF) (C, F) in relation
with degree of neovascularization (A–C) and degree of fibrosis
(D–F) in the vitreous of 32 PDR patients. Vertical bars represent
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Furthermore, several growth factors have been suggested to play
a role in angiogenesis and fibrosis in ocular disease [5,6], which
may also have influence on the presence and availability of VEGF
and/or CTGF.
Our findings suggest that the balance between VEGF and
CTGF determines the angio-fibrotic switch. This concept predicts
that a sharp decline of VEGF levels in a patient with active
neovascularization due to PDR inhibits angiogenesis, cause the
angio-fibrotic switch and temporarily increase fibrosis. In a non-
systematic survey, we studied the clinical files of a small series of
four PDR patients with active neovascularization treated with
intravitreal bevacizumab, an anti-VEGF antibody, and/or pan-
retinal laser. Pan-retinal photocoagulation is a therapy which
destroys large areas of retina, and which is known to markedly
reduce intra-ocular VEGF levels [26]. In these four patients, we
did indeed observe regression of neovascularization and the
predicted temporary increase in fibrosis. In another patient with
branch retinal vein occlusion complicated by focal pre-retinal
neovascularization, fibrosis did not follow laser treatment. This
suggests that for the angio-fibrotic switch to occur, CTGF levels
need to reach a threshold value and a sufficient number of target
cells must be able to elicit the fibrotic response. Therefore, intra-
ocular fibrosis appears to be a tightly regulated on-off response,
like intra-ocular angiogenesis.
Existing literature supports our general concept. The role of
CTGF as pro-fibrotic factor is well-established in various organs
such as skin and kidney [11–13,15,27–31,43,48–50] and recently
in the retina as well [10,51]. Furthermore, mRNA and protein of
CTGF is upregulated by VEGF in retinal endothelial cells [16–18]
and co-localizes with VEGF in neovascular subretinal membranes
of patients with age-related macular disease [23]. In these
Figure 3. Fundus photographs of a patient with proliferative diabetic retinopathy and new vessels (nv) along the lower vascular
arcade, before (A) and 8 months after (B) an injection with bevacizumab followed by pan-retinal photocoagulation. Note the increase
in fibrosis (f) after anti-VEGF and laser treatment (B).
doi:10.1371/journal.pone.0002675.g003
Table 2. Odds ratio (OR) and 95% confidence interval (95%CI) of the univariate ordinal logistic regression models with degree of
neovascularization or fibrosis as outcome in the PDR population (N=32), respectively.
Variable Contrast Degree of neovascularization Degree of fibrosis
OR [95% CI] P-value OR [95% CI] P-value
Female gender 0.97 [0.24–3.89] 0.965 1.25 [0.32–4.89] 0.746
Age per year 1 [0.95–1.06] 0.939 0.98 [0.93–1.04] 0.568
Types of diabetes II vs. I 1.27 [0.32–5.07] 0.74 3.21 [0.77–13.37] 0.109
Degree of haemorrhage 0.592 0.497
1 vs. 0 0.7 [0.08–6.25] 0.65 [0.07–6.29]
2 vs. 0 2.79 [0.48–16.26] 1 [0.19–5.16]
3 vs. 0 1.64 [0.22–12.01] 0.21 [0.02–1.81]
Degree of neovascularization 0.233
0 vs. 2 0.39 [0.02–8.61]
1 vs. 2 3.18 [0.70–14.53]
Degree of fibrosis 0.61
2 vs. 1 1.84 [0.10–33.09]
3 vs. 1 0.88 [0.05–16.15]
CTGF per unit increase 1.05 [0.97–1.15] 0.235 1.14 [1.03–1.27] 0.014
VEGF per 10 fold increase 94.3 [3.92 – Inf] 0.005 0.33 [0.05–2.39] 0.27
Ratio CTGF/log10(VEGF) per unit increase 1.19 [0.86–1.65] 0.283 2.05 [1.18–3.54] 0.01
doi:10.1371/journal.pone.0002675.t002
Angio-Fibrotic Switch
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[23], which are capable of transdifferentiation into myofibroblasts,
the major cell type driving fibrosis. In fibrovascular membranes of
patients with PDR and in human diabetic retina, CTGF is
localized in myofibroblasts [24] and pericytes [37] which can also
transform into myofibroblasts. Finally, in a recent study, it was not
only shown that activated human hyalocytes and Mu ¨ller cells
produce CTGF, but also that CTGF does not induce pro-
angiogenic functions in cultured human endothelial cells [44].
In summary, our results suggest that, in contrast to VEGF,
elevated CTGF levels do not significantly contribute to ocular
angiogenesis in PDR. In addition, we propose that CTGF, in a
critical balance with VEGF, drives the angio-fibrotic switch and
subsequent fibrosis in PDR. This indicates that CTGF-targeted
therapy is a possible novel option to prevent sight-threatening
fibrosis in PDR and other ocular diseases that are associated with
neovascularization and fibrosis. Our concept of the regulation of
the angio-fibrotic switch may also apply to wound healing
processes outside the eye.
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